Candy giant Mars partners with biotech firm to gene-edit cocoa supply

Candy giant Mars partners with biotech firm to gene-edit cocoa supply


Packages of M&M’s milk chocolate candy are stacked at a Costco Wholesale store on July 12, 2025 in San Diego, California.

Kevin Carter | Getty Images News | Getty Images

Candy maker Mars said Wednesday it’s partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology.

The agreement gives the M&M’s maker access to Pairwise’s Fulcrum platform, which includes a library of plant traits, and gives Mars the ability to tailor its crops to be stronger and more sustainable.

CRISPR is a gene editing tool that makes fast and precise changes to DNA. In farming, it’s used to improve crops by targeting different traits like drought and disease resistance.

The goal is to create cacao plants — the source of cacao beans, which are then roasted and made into cocoa — that can better withstand disease, heat and other climate-related stresses that can put global chocolate supply at risk.

In October, Starbucks invested in two innovation farms in Central America to protect the chain’s coffee supply from global warming. The farms develop climate-resilient coffee and test technologies like drones and mechanization.

Gene editing allows for faster and more precise trait development than traditional breeding, Pairwise said in a press release.

CRISPR has garnered attention in recent years for its applications in health care. In late 2023, the U.S. Food and Drug Administration approved the first gene-editing treatment for sickle cell disease.

“At Mars, we believe CRISPR has the potential to improve crops in ways that support and strengthen global supply chains,” said Carl Jones, Plant Sciences Director at Mars, in the release.

Last month, the candy giant announced a $2 billion investment in U.S. manufacturing through 2026. This includes a new $240 million investment for a Nature’s Bakery facility in Utah.



Source

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Health

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect

Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]

Read More
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
Health

Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. For […]

Read More
Hinge Health stock pops 6% after first quarterly report since IPO
Health

Hinge Health stock pops 6% after first quarterly report since IPO

Hinge Health co-founders, Gabriel Mecklenburg and Daniel Perez celebrate its initial public offering at the New York Stock Exchange on May 22, 2025. NYSE Shares of Hinge Health popped 6% in extended trading on Tuesday after the digital physical therapy company reported quarterly results for the first time since its debut on the New York […]

Read More